Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions

Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions

Dabigatran, rivaroxaban, apixaban, and edoxaban are direct oral anticoagulants (DOACs) that are increasingly used worldwide. Taking into account their widespread use for the prevention of thromboembolism in cardiology, neurology, orthopedics, and coronavirus disease 2019 (COVID 19) as well as their...

Bibliográfalaš dieđut
Váldodahkkit:	Natalia A. Shnayder, Marina M. Petrova, Pavel A. Shesternya, Alina V. Savinova, Elena N. Bochanova, Olga V. Zimnitskaya, Elena A. Pozhilenkova, Regina F. Nasyrova
Materiálatiipa:	Artihkal
Giella:	English
Almmustuhtton:	MDPI AG 2021-04-01
Ráidu:	Biomedicines
Fáttát:	pharmacokinetics pharmacogenetics dabigatran rivaroxaban apixaban edoxaban
Liŋkkat:	https://www.mdpi.com/2227-9059/9/5/451

Geahča maid

PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION
Dahkki: A. V. Kryukov, et al.
Almmustuhtton: (2017-07-01)

Personalized approach for direct oral anticoagulant prescription: from theory to practice
Dahkki: A I Skripka, et al.
Almmustuhtton: (2019-07-01)

Pharmacogenetics of new oral anticoagulants
Dahkki: Bella A. Azimova, et al.
Almmustuhtton: (2023-04-01)

A review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran
Dahkki: Ali Mohammed Abd Alridha, et al.
Almmustuhtton: (2022-01-01)

Are outpatient anticoagulation management services the wave of the future (again)?
Dahkki: Bethany Samuelson Bannow
Almmustuhtton: (2022-05-01)

Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice
Dahkki: Nicola Ferri, et al.
Almmustuhtton: (2022-05-01)

DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS
Dahkki: S. N. Bel'diev, et al.
Almmustuhtton: (2017-11-01)

Risk Factors of Gastrointestinal Bleeding in Patients Receiving New Oral Anticoagulants
Dahkki: Ju Yup Lee
Almmustuhtton: (2018-12-01)

Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells
Dahkki: Sergey Nikolaevich Bel'diev, et al.
Almmustuhtton: (2017-11-01)

Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells
Dahkki: Sergey Nikolaevich Bel'diev, et al.
Almmustuhtton: (2017-11-01)

Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics
Dahkki: Luca Masotti, et al.
Almmustuhtton: (2013-12-01)

IMPACT OF NON-VITAMIN K ORAL ANTI-COAGULANTS ON WARFARIN UTILISATION AND NHS BUDGET IN UK
Dahkki: Mohammed Aladul, et al.
Almmustuhtton: (2022-09-01)

Direct oral anticoagulants; a review for the non-specialist
Dahkki: Thilina Gunawardena
Almmustuhtton: (2021-11-01)

Non-Vitamin K Oral Anticoagulants Associated Bleeding and Its Antidotes
Dahkki: Thorsten Steiner, et al.
Almmustuhtton: (2018-09-01)

Direct oral anticoagulants: A new chapter in anticoagulation therapy
Dahkki: Stepanović-Petrović Radica, et al.
Almmustuhtton: (2020-01-01)

Direct oral anticoagulants: a guide for daily practice
Dahkki: Pierre Fontana, et al.
Almmustuhtton: (2016-02-01)

Evaluation of bleeding in patients receiving direct oral anticoagulants
Dahkki: Hellenbart EL, et al.
Almmustuhtton: (2017-08-01)

Anticoagulation in the early phase of non-valvular atrial fibrillation-related acute ischemic stroke: where do we stand?
Dahkki: Luca Masotti, et al.
Almmustuhtton: (2019-01-01)

Gastrointestinal Bleeding and Direct Oral Anticoagulants among Patients with Atrial Fibrillation: Risk, Prevention, Management, and Quality of Life
Dahkki: Paolo Zappulla, et al.
Almmustuhtton: (2021-04-01)

Pharmacokinetics and Pharmacogenetics of Apixaban
Dahkki: A. V. Savinova, et al.
Almmustuhtton: (2020-11-01)

Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence
Dahkki: Willett KC, et al.
Almmustuhtton: (2017-04-01)

Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: An analysis of the implications for perioperative management
Dahkki: Martina Mookadam, et al.
Almmustuhtton: (2015-01-01)

Direct oral anticoagulants and travel-related venous thromboembolism
Dahkki: Chamnanchanunt Supat, et al.
Almmustuhtton: (2018-11-01)

Evidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants
Dahkki: Konstantinos N. Aronis, et al.
Almmustuhtton: (2018-02-01)

New Direct Oral Anticoagulants (DOAC) and Their Use Today
Dahkki: Heike Schwarb, et al.
Almmustuhtton: (2016-03-01)

Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis
Dahkki: Attard LM, et al.
Almmustuhtton: (2022-10-01)

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants for Venous Thromboembolism Prophylaxis in Patients With Cancer: A Systematic Review and Trade-Off Analysis From 9 Randomized Controlled Trials
Dahkki: Yi-Dan Yan, et al.
Almmustuhtton: (2018-06-01)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
Dahkki: Michele Malagù, et al.
Almmustuhtton: (2023-03-01)

Pharmacokinetics and Pharmacogenetics of Dabigatran
Dahkki: A. V. Savinova, et al.
Almmustuhtton: (2021-03-01)

Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology
Dahkki: S. N. Bel'diev, et al.
Almmustuhtton: (2019-05-01)

Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology
Dahkki: Sergey N. Bel'diev, et al.
Almmustuhtton: (2019-05-01)

Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology
Dahkki: Sergey N. Bel'diev, et al.
Almmustuhtton: (2019-05-01)

Prerequisites and limitations of the use of oral anticoagulants in pregnant women in real-world clinical practice
Dahkki: Kh. A. Zagorodnikova, et al.
Almmustuhtton: (2025-01-01)

New oral anticoagulants and cardiac safety: do we have a problem?
Dahkki: E. M. Nifontov
Almmustuhtton: (2018-04-01)

Practical issues in measuring the anticoagulant effect of direct oral anticoagulants
Dahkki: Dopsaj Violeta
Almmustuhtton: (2020-01-01)

Prospects of oral anticoagulant therapy in patients with atrial fibrillation and chronic anemia: a narrative review
Dahkki: Tatyana S. Degtyareva, et al.
Almmustuhtton: (2024-12-01)

The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants
Dahkki: Jamshed Dalal, et al.
Almmustuhtton: (2015-12-01)

SPECIFIC ANTIDOTES TO NEW ORAL ANTICOAGULANTS
Dahkki: O. O. Shakhmatova
Almmustuhtton: (2016-07-01)

Stability of Direct Oral Anticoagulants Concentrations in Blood Samples for Accessibility Expansion of Chromogenic Assays
Dahkki: Anna Gavrilova, et al.
Almmustuhtton: (2023-07-01)

Safety and efficacy of direct oral anticoagulants in comparison to warfarin in obese patients with atrial fibrillation: A systematic review and meta‐analysis
Dahkki: Alla Adelkhanova, et al.
Almmustuhtton: (2024-04-01)